Asset Details
Do you wish to reserve the book?
Actionable Genomic Alterations in Prostate Cancer Among Black and White United States Veterans
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Actionable Genomic Alterations in Prostate Cancer Among Black and White United States Veterans
Do you wish to request the book?
Actionable Genomic Alterations in Prostate Cancer Among Black and White United States Veterans
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Actionable Genomic Alterations in Prostate Cancer Among Black and White United States Veterans
2023
Overview
Black Veterans have higher a incidence of localized and metastatic prostate cancer compared to White Veterans yet are underrepresented in reports of frequencies of somatic and germline alterations. This retrospective analysis of somatic and putative germline alterations was conducted in a large cohort of Veterans with prostate cancer (N = 835 Black, 1613 White) who underwent next generation sequencing through the VA Precision Oncology Program, which facilitates molecular testing for Veterans with metastatic cancer. No differences were observed in gene alterations for FDA approved targetable therapies (13.5% in Black Veterans vs. 15.5% in White Veterans, P = .21), nor in any potentially actionable alterations (25.5% vs. 28.7%, P =.1). Black Veterans had higher rates of BRAF (5.5% vs. 2.6%, P < .001) alterations, White Veterans TMPRSS2 fusions (27.2% vs. 11.7%, P < .0001). Putative germline alteration rates were higher in White Veterans (12.0% vs. 6.1%, P < .0001). Racial disparities in outcome are unlikely attributable to acquired somatic alterations in actionable pathways.
Black veterans have higher incidence of prostate cancer than White veterans but are underrepresented in reports of frequencies of somatic and germline alterations. This retrospective analysis of somatic and putative germline alterations was conducted in a large cohort of veterans with prostate cancer who underwent next-generation sequencing through the VA Precision Oncology Program. No differences were observed in actionable alterations, suggesting disparities in prostate cancer outcomes are not attributable to acquired somatic alterations in actionable pathways.
Publisher
Oxford University Press
